Viewing nowLoical Soft Capsule (Calcitriol)
Calcitriol 0.25μg
Soft capsule · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

MFDS item code 199700041 · Notified 1997.03.24 · Insurance code 648500590
Treatment of renal osteodystrophy, parathyroid dysfunction, and bone disorders (osteoporosis, rickets, etc.)
This medication is used to treat secondary hyperparathyroidism and metabolic bone disease occurring in patients with chronic renal failure before dialysis therapy. It is also effective in renal osteodystrophy in patients undergoing dialysis. It helps in the treatment of hypoparathyroidism, such as post-surgical or idiopathic, pseudohypoparathyroidism. It is used for rickets or osteomalacia, especially vitamin D-dependent rickets and hypophosphatemic vitamin D-resistant rickets. Finally, it is utilized in the treatment of osteoporosis. It is used to improve various bone metabolic diseases.
The optimal daily dose of this medicine must be carefully determined for each patient based on serum calcium levels. Initiate treatment at the lowest possible dose, and do not increase the dose without close monitoring of serum calcium. ○ Patients before the dialysis treatment stage: The initial recommended dose for adults is 0.25 ㎍ of calcitriol daily; if necessary, it may be increased to 0.5 ㎍ daily. ○ Renal osteodystrophy (patients on dialysis): The initial daily dose is 0.25 ㎍ of this medicine. For patients whose serum calcium levels are within the normal range or slightly low, administer 0.25 ㎍ every other day. If there is an inadequate response in biochemical test results and clinical symptoms, increase the dose by 0.25 ㎍ daily at intervals of 2 ~ 4 weeks. During this period, measure serum calcium at least twice weekly. Most patients respond to a dose of 0.5 ~ 1.0 ㎍ daily. This medicine improves calcium absorption from the gastrointestinal tract, so some patients taking this medicine may be maintained with a lower calcium intake. Patients prone to developing hypercalcemia may require only a small amount of calcium or no calcium supplementation at all. ○ Osteoporosis: Administer 0.25 ㎍ of this medicine twice daily. During the dose stabilization period, measure serum calcium at least twice weekly. If hypercalcemia is observed, discontinue administration until serum calcium returns to normal. As this medicine increases calcium absorption in postmenopausal patients with osteoporosis, calcium supplementation may not be necessary. ○ Hypoparathyroidism and rickets/osteomalacia: As the initial dose, it is preferable to administer 0.25 ㎍ of this medicine every morning. If there is an inadequate response in biochemical test results and clinical symptoms, increase the dose at intervals of 2 ~ 4 weeks. During dose determination, measure serum calcium at least twice weekly. Malabsorption sometimes occurs in patients with hypoparathyroidism, and a higher dose may therefore be required. ○ General information: Once the optimal dose of this medicine has been determined, measure serum calcium once monthly. Collect blood samples for serum calcium measurement without a tourniquet. If serum calcium rises by 1 mg/dL (250 μmol/L) above the normal range of 9 ~ 11 mg/dL (2,250 ~ 2,750 μmol/L), or serum creatinine rises to 120 μmol/L or higher, promptly reduce the dose sufficiently or discontinue administration until serum calcium returns to normal. Discontinuing supplemental calcium is also effective for rapidly normalizing serum calcium. Carefully consider reducing dietary calcium intake as well. During hypercalcemia, measure serum calcium and phosphorus daily. Once levels return to normal, resume treatment at a dose 0.25 ㎍ lower per day than the previous dose.
Children aged 36 months or older: 0.25 ㎍ of calcitriol daily; if necessary, it may be increased to 0.5 ㎍ daily. Children younger than 36 months: The initial recommended dose is 10 ~ 15 ng/kg of body weight daily.
This drug should not be used in patients with diseases associated with hypercalcemia or hypercalciuria. Also, it should not be administered to patients with allergies to this drug or similar drugs, those with symptoms of vitamin D toxicity, and patients with primary hyperparathyroidism. It should be used cautiously in pregnant women or those who may become pregnant, nursing mothers, children under 36 months, children receiving hemodialysis, patients with a history of kidney stones, and sarcoidosis patients. This drug, being an active metabolite of vitamin D, can cause symptoms similar to hypercalcemia if overdosed, which can lead to adverse reactions from various systems including digestive, neurological, circulatory, sensory, skeletal, respiratory, urinary, liver, kidney, skin, and eyes. Adequate calcium intake is essential during treatment, and one should be careful not to exceed the recommended daily intake of calcium. To prevent overdose, serum calcium levels should be routinely checked and dose adjusted to maintain normal ranges. Particularly, if symptoms of hypercalcemia appear, the medication should be discontinued immediately, and consultation with healthcare providers is recommended. This drug may interact with other vitamin D preparations or calcium supplements, certain diuretics, digitalis, etc., therefore caution is required when combined. Pregnant or nursing women should use this drug cautiously as it may affect the fetus or newborn, under the physician’s judgment. In children or the elderly, adjustments in dosage and closer monitoring of serum calcium levels are warranted due to potential differences in bodily function. In case of overdose, emergency treatments such as inducing vomiting or gastric lavage are needed, and appropriate treatment for symptoms due to hypercalcemia should be carried out. Care should be taken when driving or operating machinery while on this medication, as overdose may impair these abilities. For storage, keep it out of reach of children, avoid light and moisture, and store it below 25 degrees Celsius. Medications should be kept in their original container to prevent quality degradation or misuse.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering, ideally between 1 to 30 degrees Celsius at room temperature. This storage method helps to maintain the effectiveness of the medication and prevents degradation.
Oval soft capsules that contain a colorless or transparent liquid, with a milky white color.
60 capsules/PTP, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCalcitriol 0.25μg
Soft capsule · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Calcitriol 0.25μg
Soft capsule · Prescription medication
Yuyu Pharmaceutical Co., Ltd.

Calcitriol 0.25μg
Soft capsule · Prescription medication
Korea PMG Pharmaceutical Co., Ltd.

Calcitriol 0.25μg
Soft capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Calcitriol 0.25μg
Soft capsule · Prescription medication
GP Therapeutics Korea Co., Ltd.
Calcitriol 1μg
Injections · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.